# Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

> **NCT00410423** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 55 (actual)

## Conditions studied

- Relapsed Acute Leukemia
- Refractory Acute Leukemia

## Interventions

- **DRUG:** Bortezomib with mitoxantrone, etoposide and cytarabine
- **DRUG:** Bortezomib 1.0mg/m^2
- **DRUG:** Bortezomib 1.3mg/m^2

## Key facts

- **NCT ID:** NCT00410423
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2013-05
- **Final completion:** 2014-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410423, "Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00410423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*